A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis

Fulvestrant is recommended for the hormone receptor-positive metastatic breast cancer (MBC) patients progressed during or after prior endocrine therapy. Notably, recent evidence has also demonstrated that adding a targeted agent to fulvestrant conferred a significantly clinical benefit in these pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Liang, Yan, Ningning, Li, Zhihua, Luo, Lihua, Wu, Xiaobo, Liu, Qiuming, Xu, Yingchun, Cao, Yali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267349/
https://www.ncbi.nlm.nih.gov/pubmed/30568462
http://dx.doi.org/10.2147/OTT.S166653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267349/
https://www.ncbi.nlm.nih.gov/pubmed/30568462
http://dx.doi.org/10.2147/OTT.S166653

Ejemplares similares